[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

The old CEACAMs find their new role in tumor immunotherapy

  • Review
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

A Correction to this article was published on 22 June 2020

This article has been updated

Summary

Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) contain 12 family members(CEACAM1、CEACAM3、CEACAM4、CEACAM5、CEACAM6、CEACAM7、CEACAM8、CEACAM16、CEACAM18、CEACAM19、CEACAM20 and CEACAM21)and are expressed diversely in different normal and tumor tissues. CEA (CEACAM5) has been used as a tumor biomarker since 1965. Here we review the latest research and development of the structures, expression, and function of CEACAMs in normal and tumor tissues, and their application in the tumor diagnosis, prognosis, and treatment. We focus on recent clinical studies of CEA targeted cancer immunotherapies, including bispecific antibody (BsAb) for radio-immuno-therapy and imaging, bispecific T cell engager (BiTE) and chimeric antigen receptor T cells (CAR-T). We summarize the promising clinical relevance and challenges of these approaches and give perspective view for future research. This review has important implications in understanding the diversified biology of CEACAMs in normal and tumor tissues, and their new role in tumor immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 2

Similar content being viewed by others

Change history

  • 22 June 2020

    Correction is needed to the original version of this article.

Abbreviations

BiTE:

Bispecific T Cell Engager.

BsAb:

Bispecific Antibody.

CEA:

Carcinoembryonic Antigen.

CEACAM:

Carcinoembryonic Antigen-Related Cell Adhesion Molecule.

CAR-T:

Chimeric Antigen Receptor T Cell.

HSG:

Histamine-succinylglycine.

Ig:

Immunoglobulin.

TAA:

Tumor-associated antigens.

HAI:

Hepatic Intraarterial Infusion.

SIRT:

Selective Internal Radiation Therapy.

References

  1. Taheri M et al (2000) Self recognition in the Ig superfamily. Identification of precise subdomains in carcinoembryonic antigen required for intercellular adhesion. J Biol Chem 275(35):26935–26943

    CAS  PubMed  Google Scholar 

  2. Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122(3):467–481

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Beauchemin N, Arabzadeh A (2013) Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev 32(3–4):643–671

    CAS  PubMed  Google Scholar 

  4. Kuespert K, Pils S, Hauck CR (2006) CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 18(5):565–571

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Horst AK, Wagener C (2004) CEA-Related CAMs. Handb Exp Pharmacol 165:283–341

    CAS  Google Scholar 

  6. Gray-Owen SD, Blumberg RS (2006) CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 6(6):433–446

    CAS  PubMed  Google Scholar 

  7. Sedykh SE et al (2018) Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther 12:195–208

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941–4944

    CAS  PubMed  Google Scholar 

  9. Frankel SR, Baeuerle PA (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 17(3):385–392

    CAS  PubMed  Google Scholar 

  10. Wolf E et al (2005) BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10(18):1237–1244

    CAS  PubMed  Google Scholar 

  11. Kochenderfer JN et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540–549

    CAS  PubMed  Google Scholar 

  12. Offner S et al (2006) Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43(6):763–771

    CAS  PubMed  Google Scholar 

  13. Naghibalhossaini F, Stanners CP (2004) Minimal mutations are required to effect a radical change in function in CEA family members of the Ig superfamily. J Cell Sci 117(Pt 5):761–769

    CAS  PubMed  Google Scholar 

  14. Dery KJ et al (2011) Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M. J Biol Chem 286(18):16039–16051

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Wang L et al (2000) C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers. Clin Cancer Res 6(8):2988–2993

    CAS  PubMed  Google Scholar 

  16. Markel G et al (2004) Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur J Immunol 34(8):2138–2148

    CAS  PubMed  Google Scholar 

  17. Simeone DM et al (2007) CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34(4):436–443

    CAS  PubMed  Google Scholar 

  18. Tilki D et al (2010) CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol 57(4):648–654

    CAS  PubMed  Google Scholar 

  19. Dankner M et al (2017) CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology 6(7):e1328336

    PubMed  PubMed Central  Google Scholar 

  20. Frangsmyr L et al (1995) Cell- and region-specific expression of biliary glycoprotein and its messenger RNA in normal human colonic mucosa. Cancer Res 55(14):2963–2967

    CAS  PubMed  Google Scholar 

  21. Nolan KF et al (1999) Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 5(12):3928–3941

    CAS  PubMed  Google Scholar 

  22. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9(2):67–81

    CAS  PubMed  Google Scholar 

  23. Nap M et al (1988) Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 9(2–3):145–153

    CAS  PubMed  Google Scholar 

  24. Yan Z et al (1997) Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J Biol Chem 272(44):27902–27907

    CAS  PubMed  Google Scholar 

  25. Scholzel S et al (2000) Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol 156(2):595–605

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Gambichler T et al (2009) Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions. Am J Clin Pathol 131(6):782–787

    PubMed  Google Scholar 

  27. Thies A et al (2007) Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases. Cancer Lett 248(1):68–80

    CAS  PubMed  Google Scholar 

  28. Neumaier M et al (1993) Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc Natl Acad Sci U S A 90(22):10744–10748

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Kunath T et al (1995) Inhibition of colonic tumor cell growth by biliary glycoprotein. Oncogene 11(11):2375–2382

    CAS  PubMed  Google Scholar 

  30. Nollau P et al (1997) Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Cancer Res 57(12):2354–2357

    CAS  PubMed  Google Scholar 

  31. Turbide C et al (1997) Optimal ratios of biliary glycoprotein isoforms required for inhibition of colonic tumor cell growth. Cancer Res 57(13):2781–2788

    CAS  PubMed  Google Scholar 

  32. Izzi L et al (1999) cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function. Oncogene 18(40):5563–5572

    CAS  PubMed  Google Scholar 

  33. Yeatman TJ, Mao W, Karl RC (1997) Biliary glycoprotein is overexpressed in human colon cancer cells with high metastatic potential. J Gastrointest Surg 1(3):292–298

    CAS  PubMed  Google Scholar 

  34. Kang WY et al (2007) The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Colorectal Dis 22(8):869–874

    PubMed  Google Scholar 

  35. Song JH et al (2011) Genetic alterations and expression pattern of CEACAM1 in colorectal adenomas and cancers. Pathol Oncol Res 17(1):67–74

    CAS  PubMed  Google Scholar 

  36. Ou G et al (2009) Contribution of intestinal epithelial cells to innate immunity of the human gut–studies on polarized monolayers of colon carcinoma cells. Scand J Immunol 69(2):150–161

    CAS  PubMed  Google Scholar 

  37. Arabzadeh A et al (2016) Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells. Gut 65(5):821–829

    CAS  PubMed  Google Scholar 

  38. Zhou MQ et al (2013) Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer. BMC Cancer 13:359

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Sienel W et al (2003) Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 9(6):2260–2266

    CAS  PubMed  Google Scholar 

  40. Nolen BM et al (2015) Urinary protein biomarkers in the early detection of lung cancer. Cancer Prev Res (Phila) 8(2):111–119

    CAS  Google Scholar 

  41. Gong DY et al (2011) [Diagnostic value of serum CEACAM1 in patients with pancreatic cancer]. Nan Fang Yi Ke Da Xue Xue Bao 31(1):164–166

    PubMed  Google Scholar 

  42. Giulietti M et al (2016) Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell Oncol (Dordr) 39(4):379–388

    CAS  Google Scholar 

  43. Gebauer F et al (2014) Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS One 9(11):e113023

    PubMed  PubMed Central  Google Scholar 

  44. Oliveira-Ferrer L et al (2004) Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res 64(24):8932–8938

    CAS  PubMed  Google Scholar 

  45. Kleinerman DI et al (1996) Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res 56(15):3431–3435

    CAS  PubMed  Google Scholar 

  46. Yang M et al (2015) T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. J Surg Oncol 112(4):430–435

    CAS  PubMed  Google Scholar 

  47. Fichera A, Michelassi F, Arenas RB (1998) Selective expression of carcinoembryonic antigen promoter in cancer cell lines: targeting strategy for gene therapy in colorectal cancer. Dis Colon Rectum 41(6):747–754

    CAS  PubMed  Google Scholar 

  48. Tiernan JP et al (2013) Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer 108(3):662–667

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Hanenberg H et al (1994) Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin. Leukemia 8(12):2127–2133

    CAS  PubMed  Google Scholar 

  50. Jantscheff P et al (2003) Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol 21(19):3638–3646

    CAS  PubMed  Google Scholar 

  51. Kim KS et al (2013) Overexpression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in colorectal cancer. Clin Chim Acta 415:12–19

    CAS  PubMed  Google Scholar 

  52. Blumenthal RD et al (2007) Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 7:2

    PubMed  PubMed Central  Google Scholar 

  53. Thompson J et al (1994) CGM2, a member of the carcinoembryonic antigen gene family is down-regulated in colorectal carcinomas. J Biol Chem 269(52):32924–32931

    CAS  PubMed  Google Scholar 

  54. Zhou J et al (2011) Dynamic expression of CEACAM7 in precursor lesions of gastric carcinoma and its prognostic value in combination with CEA. World J Surg Oncol 9:172

    PubMed  PubMed Central  Google Scholar 

  55. Ellison LM et al (2017) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis. Chin J Cancer Res 29(1):86–92

    PubMed  PubMed Central  Google Scholar 

  56. Xin HW et al (2016) Liver label retaining cancer cells are relatively resistant to the reported anti-cancer stem cell drug metformin. J Cancer 7(9):1142–1151

  57. Xin HW et al (2013) Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division. J Cancer 4(6):447–457

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Xin HW et al (2013) Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut 62(12):1777–1786

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Xin HW et al (2012) Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 30(4):591–598

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Goel G, Sun W (2015) Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol 8:44

    PubMed  PubMed Central  Google Scholar 

  61. Ma W et al (2016) Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 9(1):47

    PubMed  PubMed Central  Google Scholar 

  62. Hirsch FR et al (2016) New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 388(10048):1012–1024

    PubMed  Google Scholar 

  63. Wang D et al (2018) CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research. Cancer Gene Ther 25(5–6):93–105

    CAS  PubMed  Google Scholar 

  64. Wang YY et al (2019) Identification of putative UL54 (ICP27) transcription regulatory sequences binding to Oct-1, v-Myb, Pax-6 and hairy in herpes simplex viruses. J Cancer 10(2):430–440

  65. Liu XQ et al (2018) Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins. Drug Deliv 25(1):1950–1962

    CAS  PubMed  PubMed Central  Google Scholar 

  66. McCardle RJ et al (1966) Studies with iodine-131-labeled antibody to human fibrinogen for diagnosis and therapy of tumors. J Nucl Med 7(11):837–847

    CAS  PubMed  Google Scholar 

  67. Wu ZJ et al (2018) Oncolytic viruses for tumor precision imaging and radiotherapy. Hum Gene Ther 29(2):204–222

  68. Abdel Razek AAK (2018) Routine and advanced diffusion imaging modules of the salivary glands. Neuroimaging Clin N Am 28(2):245–254

  69. Abdel Razek AAK et al (2019) Clinical applications of arterial spin labeling in brain tumors. J Comput Assist Tomogr 43(4):525–532

  70. Razek AA, Nada N (2016) Correlation of choline/creatine and apparent diffusion coefficient values with the prognostic parameters of head and neck squamous cell carcinoma. NMR Biomed 29(4):483–489

  71. Goldenberg DM et al (1978) Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298(25):1384–1386

    CAS  PubMed  Google Scholar 

  72. Dallas MR et al (2012) Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J 26(6):2648–2656

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Francis RJ et al (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 87(6):600–607

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Reck M, Heigener D, Reinmuth N (2016) Immunotherapy for small-cell lung cancer: emerging evidence. Future Oncol 12(7):931–943

    CAS  PubMed  Google Scholar 

  75. Schoffelen R et al (2010) Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68 Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 9(4):1019–1027

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Bodet-Milin C et al (2019) Clinical results in medullary thyroid carcinoma suggest high potential of pretargeted immuno-PET for tumor imaging and theranostic approaches. Front Med (Lausanne) 6:124

  77. Sharkey RM et al (2010) Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 40(3):190–203

    PubMed  PubMed Central  Google Scholar 

  78. Bodet-Milin C et al (2016) Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68 Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in-human trial. J Nucl Med 57(10):1505–1511

  79. Foubert F et al (2018) Sensitivity of pretargeted immunoPET using (68)Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: comparison with (18)FDG PET-CT. Oncotarget 9(44):27502–27513

  80. Zhao Y et al (2020) Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies. Cancer Biol Ther 21(1):72–80

    CAS  PubMed  Google Scholar 

  81. Bodet-Milin C et al (2015) Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA-expressing advanced lung cancer patients. Front Med (Lausanne) 2:84

  82. Moek KL et al (2019) 89Zr-labeled bispecific T-cell engager AMG 211 PET shows AMG 211 accumulation in CD3-rich tissues and clear, heterogeneous tumor uptake. Clin Cancer Res

  83. Pishvaian M et al (2016) Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas. Clin Colorectal Cancer 15(4):345–351

  84. Brischwein K et al (2007) Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 30(8):798–807

    CAS  PubMed  Google Scholar 

  85. Hoffmann P et al (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 115(1):98–104

    CAS  PubMed  Google Scholar 

  86. Molhoj M et al (2007) CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 44(8):1935–1943

    CAS  PubMed  Google Scholar 

  87. Amann M et al (2009) Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 32(5):452–464

    CAS  PubMed  Google Scholar 

  88. Oberst MD et al (2014) CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 6(6):1571–1584

    PubMed  PubMed Central  Google Scholar 

  89. Pan H et al (2018) Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy. Int J Nanomedicine 13:3189–3201

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Thistlethwaite FC et al (2017) The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother 66(11):1425–1436

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Zhang C et al (2017) Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther 25(5):1248–1258

  92. Katz SC et al (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA + liver metastases. Clin Cancer Res 21(14):3149–3159

  93. Hombach AA, Rappl G, Abken H (2019) Blocking CD30 on T cells by a dual specific CAR for CD30 and colon cancer antigens improves the CAR T cell response against CD30(-) Tumors. Mol Ther 27(10):1825–1835

  94. Katz SC et al (2019) HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases. Cancer Gene Ther

Download references

Funding

This work was mainly supported by National Natural Science Foundation of China (81872412 to XHW, 81602303 to XY, 31700736 to WXW). We thank Hubei Province Natural Science Foundation of China (2016CFB180 to WXW), Foundation of Health and Family Planning Commission of Hubei Province (WJ2016-Y-02 To MZ, WJ2016Y07 To WXW), Hubei Province Scientific and Technological Research Project (Q20171306 to XWW), Jingzhou Science and Technology Development Planning Project (JZKJ15063 to WXW), and Guangzhou Key Medical Discipline Construction Project (CSZ).

Author information

Author notes

  1. Zi-Wen Han, Zhi-Wu Lyv and Bin Cui contributed equally to this work.

Authors and Affiliations

  1. Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei, 434023, China

    Zi-Wen Han, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Wen-Qi Cai, Yang Zhou, Zhao-Wu Ma, Xian-Wang Wang, Xiao-Chun Peng, Ying Xiang & Hong-Wu Xin

  2. Department of Biochemistry and Molecular Biology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei, 434023, China

    Zi-Wen Han, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Wen-Qi Cai, Yang Zhou, Zhao-Wu Ma, Xian-Wang Wang, Xiao-Chun Peng, Ying Xiang & Hong-Wu Xin

  3. Department of Pathology, Lianjiang People’s Hospital, Zhanjiang, Guangdong, 524400, China

    Zhi-Wu Lyv & Bin Cui

  4. Department of Laboratory Medicine, School of Basic Medicine, Health Science Center, Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei, 434023, China

    Xian-Wang Wang

  5. Department of Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei, 434023, China

    Xiao-Chun Peng

  6. State Key Laboratory of Respiratory Disease, Affiliated Cancer Hospital Institute of Guangzhou Medical University, Guangzhou, 510095, China

    Shu-Zhong Cui

  7. The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, 11 Guangdong Province, 518107, People’s Republic of China

    Mo Yang

Authors
  1. Zi-Wen Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhi-Wu Lyv
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying-Ying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun-Ting Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wen-Qi Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zhao-Wu Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xian-Wang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xiao-Chun Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shu-Zhong Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ying Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hong-Wu Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ying Xiang, Mo Yang or Hong-Wu Xin.

Ethics declarations

Conflict of interest

No conflict of interest in this work.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, ZW., Lyv, ZW., Cui, B. et al. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs 38, 1888–1898 (2020). https://doi.org/10.1007/s10637-020-00955-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-020-00955-w

Keywords

Search

Navigation